New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
07:35 EDTNLNKNewLink Genetics price target raised to $35 from $23 at Canaccord
Canaccord is more optimistic that the P3 IMPRESS trial of HyperAcute Pancreas in resected pancreatic cancer could meet its primary endpoint of an improvement in overall survival vs. placebo following a management meeting. Shares are Buy rated.
News For NLNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
10:06 EDTNLNKOptions with decreasing implied volatility
Subscribe for More Information
06:28 EDTNLNKFujifilm CEO says 'ready' for large orders of Avigan drug for Ebola, WSJ reports
Fujifilm’s (FUJIY) Avigan drug, which has shown signs of efficacy against the Ebola virus, has drawn interest from about 20 countries, The Wall Street Journal reports, citing comments made by CEO Shigetaka Komori. The drug was developed by Toyama Chemical, a Fujifilm unit, and Komori said the company is ready for large orders. Other drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
February 27, 2015
10:32 EDTNLNKOptions with decreasing implied volatility
Subscribe for More Information
February 26, 2015
13:57 EDTNLNKNewLink Genetics volatility pulls back after Q4
Subscribe for More Information
10:36 EDTNLNKOptions with decreasing implied volatility
Subscribe for More Information
February 25, 2015
10:37 EDTNLNKOptions with decreasing implied volatility
Options with decreasing implied volatility: FUEL GREK NLNK HLSS SLXP LL VNDA AWAY DWA TRUE
February 19, 2015
08:38 EDTNLNKNewLink reports clinical development milestone achieved with Merck for rVSV-EBOV
NewLink Genetics (NLNK) announced that it had received notification from Merck (MRK) that the milestone event specified in the license and collaboration agreement between the two companies relating to the further development of the rVSV-EBOV, Ebola, vaccine candidate had been achieved. Under the terms of the agreement, NewLink Genetics will receive a payment of $20M in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
February 18, 2015
10:42 EDTNLNKOptions with increasing implied volatility: NLNK TLM
Subscribe for More Information
10:39 EDTNLNKNewLink Genetics volatility elevated
NewLink Genetics February call option implied volatility of 159, March s at 149, April is at 135; compared to its 26-week average of 130 according to Track Data, suggesting large price movement.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use